Brief: Windtree Therapeutics Entered Amendment No. 1 To License Agreement With Philip Morris Products S.A.

Windtree Therapeutics

17/01/2024 13:25

Jan 17 (Reuters) - Windtree Therapeutics Inc  WINT.O :
    * WINDTREE THERAPEUTICS -  ON JAN 12, CO ENTERED INTO
LICENSE,
DEVELOPMENT & COMMERCIALIZATION AGREEMENT WITH LEE'S
PHARMACEUTICAL (HK) LTD
    * WINDTREE THERAPEUTICS - CO MAY RECEIVE UP TO $3.1 MILLION
IN
POTENTIAL UPFRONT PRE-DEVELOPMENT, DEVELOPMENT, CLINICAL,
REGULATORY MILESTONE PAYMENTS
    * WINDTREE THERAPEUTICS - UNDER THE LEE’S LICENSE AGREEMENT,
CO
MAY RECEIVE  UP TO $135.25 MILLION IN SALES MILESTONE PAYMENTS
    * WINDTREE THERAPEUTICS INC - COMPANY IS ALSO ENTITLED TO
RECEIVE
A LOW DOUBLE-DIGIT PERCENTAGE OF LEE’S NON-ROYALTY SUBLICENSE
INCOME
    * WINDTREE THERAPEUTICS- ON JAN 16, ENTERED AMENDMENT NO. 1
TO
AMENDED & RESTATED LICENSE AGREEMENT WITH PHILIP MORRIS USA INC.
EFFECTIVE AS OF JAN 17
    * WINDTREE THERAPEUTICS- AMENDMENT AMENDED AMENDED AND
RESTATED
LICENSE AGREEMENT, DATED MARCH 28, 2008, BETWEEN COMPANY AND
PHILIP MORRIS USA
    * WINDTREE THERAPEUTICS- ON JAN 16, CO ENTERED AMENDMENT NO.
1 TO
LICENSE AGREEMENT WITH PHILIP MORRIS PRODUCTS S.A. EFFECTIVE AS
OF JANUARY 17, 2024

Further company coverage:  WINT.O 

 ((Reuters.Briefs@thomsonreuters.com;))